ID

45925

Descripción

Principal Investigator: Francine Garrett-Bakelman, MD, PhD, University of Virginia, Charlottesville, VA, USA; Weill Cornell Medical College, New York, NY, USA MeSH: Acute Myeloid Leukemia https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001027 Acute Myeloid Leukemia (AML) remains a clinical challenge since most patients diagnosed with AML will die from the disease. Some patients harbor treatment-refractory disease and many others relapse with disease that in many cases is resistant to treatments. Our study was designed to understand the molecular basis of disease progression in AML through assessing genomics signatures in patient specimens collected through an international collaboration which assembled samples from 138 AML patients which experienced disease relapse and normal hematopoietic cells (n=15). It is hoped that this resource will help researchers understand mechanisms of disease relapse in AML and contribute to the general pool of data available for analyses for this disease and general research use.

Link

dbGaP study = phs001027

Palabras clave

Versiones (1)
  1. 27/2/24 27/2/24 - Simon Heim
Titular de derechos de autor

Francine Garrett-Bakelman, MD, PhD, University of Virginia, Charlottesville, VA, USA; Weill Cornell Medical College, New York, NY, USA

Subido en

27 de febrero de 2024

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

dbGaP phs001027 Epigenomics Studies in Acute Myeloid Leukemia (AML)

Inglés

Eligibility Criteria

6 formularios  
Inclusion and exclusion criteria
Descripción

Inclusion and exclusion criteria

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
Inclusion and exclusion criteria for specimens included:
Descripción

Inclusion and exclusion criteria for specimens included:

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C0680251
UMLS CUI [1,3]
C0370003
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
Descripción

Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1512693
UMLS CUI [1,2]
C2735298
UMLS CUI [1,3]
C5206782
UMLS CUI [1,4]
C4272796
UMLS CUI [1,5]
C1521750
UMLS CUI [1,6]
C0282564
UMLS CUI [1,7]
C0604937
UMLS CUI [1,8]
C0587348
UMLS CUI [1,9]
C0470187
UMLS CUI [1,10]
C2707520
UMLS CUI [1,11]
C1442880
UMLS CUI [1,12]
C0011900
UMLS CUI [1,13]
C0035020
UMLS CUI [2,1]
C3845275
UMLS CUI [2,2]
C0150103
UMLS CUI [2,3]
C5192904
UMLS CUI [2,4]
C0001779
UMLS CUI [2,5]
C0686906
UMLS CUI [2,6]
C0018939
UMLS CUI [2,7]
C5205410
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
Descripción

Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0680251
UMLS CUI [1,2]
C0023487
UMLS CUI [1,3]
C0087111
UMLS CUI [1,4]
C0282564
UMLS CUI [1,5]
C0604937
UMLS CUI [1,6]
C0857127
UMLS CUI [2,1]
C0205336
UMLS CUI [2,2]
C3843629
UMLS CUI [2,3]
C0332137
Volver a la parte superior de la página

Similar models

Eligibility Criteria

6 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Inclusion and exclusion criteria
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
Inclusion and exclusion criteria for specimens included:
Item
Inclusion and exclusion criteria for specimens included:
boolean
C1512693 (UMLS CUI [1,1])
C0680251 (UMLS CUI [1,2])
C0370003 (UMLS CUI [1,3])
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
Item
Inclusion criteria: patients diagnosed with non-M3 Acute Myeloid Leukemia (AML), who received induction chemotherapy treatment with combination chemotherapy including, but not limited to an anthracycline and cytosine arabinoside, and patients from whom specimens with high blast cell percentages were available from diagnosis and relapse time points. Patient-matched germline specimens were collected in a sub-set of patients, and age-matched controls were obtained from individuals without any known hematological conditions with CD34+ cell enrichment greater than 90%.
boolean
C1512693 (UMLS CUI [1,1])
C2735298 (UMLS CUI [1,2])
C5206782 (UMLS CUI [1,3])
C4272796 (UMLS CUI [1,4])
C1521750 (UMLS CUI [1,5])
C0282564 (UMLS CUI [1,6])
C0604937 (UMLS CUI [1,7])
C0587348 (UMLS CUI [1,8])
C0470187 (UMLS CUI [1,9])
C2707520 (UMLS CUI [1,10])
C1442880 (UMLS CUI [1,11])
C0011900 (UMLS CUI [1,12])
C0035020 (UMLS CUI [1,13])
C3845275 (UMLS CUI [2,1])
C0150103 (UMLS CUI [2,2])
C5192904 (UMLS CUI [2,3])
C0001779 (UMLS CUI [2,4])
C0686906 (UMLS CUI [2,5])
C0018939 (UMLS CUI [2,6])
C5205410 (UMLS CUI [2,7])
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
Item
Exclusion criteria: patients with M3 AML (Acute Promyelocytic Leukemia), patients who received treatments not including an anthracycline and cytosine arabinoside during induction treatment, patients who relapsed more than five years after the original diagnosis.
boolean
C0680251 (UMLS CUI [1,1])
C0023487 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,3])
C0282564 (UMLS CUI [1,4])
C0604937 (UMLS CUI [1,5])
C0857127 (UMLS CUI [1,6])
C0205336 (UMLS CUI [2,1])
C3843629 (UMLS CUI [2,2])
C0332137 (UMLS CUI [2,3])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial